What if we could see disease processes at the cellular level in intact, whole tissue – without cutting it up?
FLASH Tissue Diagnostics' (FLASH TD) proprietary technology, the FLASH method, offers a unique solution for improving tissue transparency and enabling the precise detection of individual cells and subcellular components. The company has a strong focus on improving the analysis of sentinel lymph nodes—a crucial tool in cancer diagnostics—providing significant benefits in terms of cost-effectiveness, diagnostic accuracy, and reduced mortality rates.
In addition, FLASH TD leverages its technology in the emerging field of 3D spatial biology, where tissue clearing technology supports research on organoids and animal models. This drives innovations in disease modeling, drug discovery, and personalized medicine. With the growth of the market for organoid-based applications, FLASH TD is well positioned to support advances in this field.
FLASH TD's business model focuses on the rapid commercialization of its technology through strategic partnerships with established pathology companies. These collaborations enable FLASH TD to generate early revenue from research-use-only (RUO) products while paving the way for broader applications in in vitro diagnostics (IVD). The company's core strength lies in its ability to enhance existing pathology platforms, thus driving automation and efficiency within the industry.
In summary, FLASH TD is at the forefront of a rapidly growing pathology market with a disruptive technology that has enormous potential to improve cancer diagnostics and research. Thanks to strong market demand, strategic partnerships, and an innovative product offering, FLASH TD is excellently positioned to take a leadership role in the evolving 3D pathology and research landscape.
FLASH TD is led by world-class experts in cancer research and diagnostics. Co-founders Prof. Axel Behrens and Dr. Hendrik Messal pioneered the breakthrough FLASH diagnostic technology, as described in their landmark 2019 Nature publication. Both are co-inventors on the patent protecting this innovation.
